Patents by Inventor Hendrika Maria Gerarda Willems

Hendrika Maria Gerarda Willems has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS
    Publication number: 20220089590
    Abstract: The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Application
    Filed: June 17, 2021
    Publication date: March 24, 2022
    Inventors: Anthony William James Cooper, Nicole Cathleen Goodwin, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Jeffrey K. Kerns, Hendrika Maria Gerarda Willems, Hongxing Yan
  • Ether linked triazoles as NRF2 activators
    Patent number: 11059816
    Abstract: The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: July 13, 2021
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, ASTEX THERAPEUTICS LIMITED
    Inventors: Anthony William James Cooper, Nicole Cathleen Goodwin, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Jeffrey K. Kerns, Hendrika Maria Gerarda Willems, Hongxing Yan
  • N-ARYL PYRAZOLES AS NRF2 REGULATORS
    Publication number: 20200071310
    Abstract: The present invention relates to N-aryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: December 11, 2017
    Publication date: March 5, 2020
    Inventors: Brian W. BUDZIK, Peng LI, Joseph E. PERO, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, David NORTON, Hendrika Maria Gerarda WILLEMS, Alison Jo-Anne WOOLFORD
  • ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS
    Publication number: 20200071317
    Abstract: The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.
    Type: Application
    Filed: December 11, 2017
    Publication date: March 5, 2020
    Inventors: Anthony William James COOPER, Nicole Cathleen GOODWIN, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, Jeffrey K. KERNS, Hendrika Maria Gerarda WILLEMS, Hongxing YAN
  • Biaryl pyrazoles as NRF2 regulators
    Patent number: 10364256
    Abstract: The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: July 30, 2019
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics Limited
    Inventors: James Callahan, Jeffrey K. Kerns, Peng Li, Tindy Li, Brent W. McCleland, Hong Nie, Joseph E. Pero, Thomas Glanmor Davies, Maria Grazia Carr, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, David Norton, Marinus Leendert Verdonk, Alison Jo-Anne Woolford, Hendrika Maria Gerarda Willems
  • NRF2 Regulators
    Publication number: 20190002454
    Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Inventors: Jeffrey Charles BOEHM, Thomas Glanmor DAVIES, Alison Jo-Anne WOOLFORD, Charlotte Mary GRIFFITHS-JONES, Hendrika Maria Gerarda WILLEMS, David NORTON, Gordon SAXTY, Thomas Daniel HEIGHTMAN, Tindy LI, Jeffrey K. KERNS, Roderick S. DAVIS, Hongxing YAN
  • Nrf2 regulators
    Patent number: 10144731
    Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: December 4, 2018
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Astex Therapeutics, Ltd
    Inventors: Thomas Glanmor Davies, Alison Jo-anne Woolford, Hendrika Maria Gerarda Willems, David Norton, Thomas Daniel Heightman, Jeffrey K. Kerns
  • BIARYL PYRAZOLES AS NRF2 REGULATORS
    Publication number: 20180282349
    Abstract: The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: October 6, 2016
    Publication date: October 4, 2018
    Inventors: James CALLAHAN, Jeffrey K. KERNS, Peng LI, Tindy LI, Brent W. McCLELAND, Hong NIE, Joseph E. PERO, Thomas Glanmor DAVIES, Maria GRAZIA CARR, Charlotte Mary GRIFFITHS-JONES, Thomas Daniel HEIGHTMAN, David NORTON, Marinus Leedert VERDONK, Alison Jo-Anne WOOLFORD, Hendrika Maria Gerarda WILLEMS
  • Nrf2 REGULATORS
    Publication number: 20180179167
    Abstract: The present invention relates to aryl analogs Formula (I), pharmaceutical compositions containing them and their use as Nrf2 regulators.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 28, 2018
    Inventors: Jeffrey K. KERNS, Tindy LI, Hongxing YAN, Thomas Daniel HEIGHTMAN, Alison Jo-Anne WOOLFORD, Charlotte Mary GRIFFITHS-JONES, Hendrika Maria Gerarda WILLEMS
  • NRF2 REGULATORS
    Publication number: 20160318917
    Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 3, 2016
    Inventors: Jeffrey Charles Boehm, Thomas Glanmor Davies, Alison Jo-anne Woolford, Charlotte Mary Griffiths-Jones, Hendrika Maria Gerarda Willems, David Norton, Gordon Saxity, Thomas Daniel Heightman, Tindy Li, Jeffrey K. Kerns, Roderick S. Davis, Hongxing Yan
  • Pharmaceutical compounds
    Patent number: 9145354
    Abstract: The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: September 29, 2015
    Assignee: ASTEX THERAPEUTICS LIMITED
    Inventors: Andrew James Woodhead, Christopher Charles Frederick Hamlett, Gilbert Ebai Besong, Gianni Chessari, Maria Grazia Carr, Alessia Millemaggi, David Norton, Susanne Maria Saalau-Bethell, Hendrika Maria Gerarda Willems, Neil Thomas Thompson, Steven Douglas Hiscock
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20150051199
    Abstract: The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections.
    Type: Application
    Filed: October 31, 2012
    Publication date: February 19, 2015
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Andrew James Woodhead, Christopher Charles Frederick Hamlett, Gilbert Ebai Besong, Gianni Chessari, Maria Grazia Carr, Alessia Millemaggi, David Norton, Susanne Maria Saalau-Bethell, Hendrika Maria Gerarda Willems, Neil Thomas Thompson, Steven Douglas Hiscock
  • SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION
    Publication number: 20140288040
    Abstract: The invention provides compounds of the formula (6): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2; CO2H; an optionally substituted acyclic C1-8 hydrocarbon group; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is selected from hydrogen and a group R2a; R2a is selected from an optionally substituted acyclic C1-8 hydrocarbon group; an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1 or 2 ring members are heteroatom ring members selected from O, N and S; and an optionally substituted bicyclic heterocyclic group of 9 or 10 ring members, of which 1 or 2 ring members are nitrogen atoms; wherein at least one of R1 and R2 is other than hydrogen; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyc
    Type: Application
    Filed: October 31, 2012
    Publication date: September 25, 2014
    Applicant: ASTEX THERAPEUTICS LIMITED
    Inventors: Andrew James Woodhead, Gianni Chessari, Gilbert Ebai Besong, Maria Grazia Carr, Steven Douglas Hiscock, Michael Alistair O'Brien, David Charles Rees, Susanne Maria Saalau-Bethell, Hendrika Maria Gerarda Willems, Neil Thomas Thompson
  • Isoindolin-1-one derivatives
    Patent number: 8258175
    Abstract: A compound of formula or a prodrug and/or a pharmaceutically acceptable salt thereof, wherein X is O, N or S; R1 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R2 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; R3 is hydrogen, halo, hydroxy, substituted or unsubstituted alloy substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; and R4-R7, is used to represent groups R4, R5, R6 and R7 which are H, OH, alkyl, alkoxy, alkylamine, hydroxyalkyl, h
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: September 4, 2012
    Assignee: Cancer Research Technology Limited
    Inventors: Hendrika Maria Gerarda Willems, Per Kallblad, Ian Robert Hardcastle, Roger John Griffin, Bernard Thomas Golding, John Lunec, Martin E. M. Noble, David R. Newell, Alan H. Calvert
  • Isoindolin-1-One Derivatives
    Publication number: 20080261917
    Abstract: A compound of formula or a prodrug and/or a pharmaceutically acceptable salt thereof, wherein X is O, N or S; R1 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R2 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; R3 is hydrogen, halo, hydroxy, substituted or unsubstituted alloy substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; and R4-R7, is used to represent groups R4, R5, R6 and R7 which are H, OH, alkyl, alkoxy, alkylamine, hydroxyalkyl, h
    Type: Application
    Filed: August 26, 2005
    Publication date: October 23, 2008
    Inventors: Hendrika Maria Gerarda Willems, Per Kallblad, Ian Robert Hardcastle, Robert John Griffin, Bernard Thomas Golding, John Lunec, Martin E.M. Noble, David R. Newell, Alan H. Calvert